布地奈德缓释胶囊3mg的2024年价格是多少钱一盒?

The price of budesonide sustained-release capsules 3mg in 2024

Currently, we know that the price of the German version of budesonide sustained-release capsules 3mgx100 capsules is about 2000-3000$, and the price is not fixed due to various factors.

Purchase channels for Budesonide sustained-release capsules 3mg

Since Budesonide sustained-release capsules 3mg have not been launched in mainland China as of January 22, 2024, they are not yet available in domestic hospital pharmacies. The current purchase channels are as follows:

1. Understand the specific purchase situation of patients or consult doctors, but it is necessary to identify the drug purchase channel and the authenticity and safety of the drug to prevent the purchase of counterfeit drugs and affect the original treatment.

2. Go to an area where budesonide sustained-release capsules are already on the market. See a doctor at a local hospital. A doctor will prescribe the medicine based on the actual condition. You can buy the medicine based on the doctor's prescription, but you need to find a regular local hospital. This method is more expensive and is not suitable for long-term medication.

3. Through the help of domestic professional overseas medical service institutions, patients can find qualified medical service institutions online, sign a contract, and guarantee that they are genuine products. The drugs will be mailed to their homes at affordable prices and are more cost-effective. Please consult customer service personnel for specific price information.

Effects of Budesonide Extended-Release Capsules

Budesonide Extended-Release Capsules are used to induce and maintain remission of mild to moderate ileocecal Crohn's disease (capsules) and ulcerative colitis (enema) as well as remission of active substances. They are first-line anti-inflammatory drugs and Locally acting glucocorticoids can inhibit the inflammatory response in the intestines and reduce the activity and severity of Crohn's disease. Moreover, budesonide sustained-release capsules can release active ingredients in the small intestine and colon, thereby reducing systemic side effects. For more side effects, click to view.

Therapeutic efficacy of budesonide extended-release capsules

A randomized controlled trial comparing budesonide extended-release capsules with control treatment.研究对象包括任何年龄段的活动性克罗恩病患者（CDAI＞150）。主要结果是在治疗第 8 至 16 周时诱导缓解（CDAI ＜ 150）。 Secondary outcomes included: time to response, mean change in CDAI, clinical, histological or endoscopic improvement, improvement in quality of life, adverse events and early discontinuation.

Trial results

A total of 12 studies were included: 9 studies compared traditional corticosteroids, 2 studies were placebo-controlled, and 1 study compared budesonide extended-release capsules with mesalazine. After 8 weeks of treatment, budesonide extended-release capsules were significantly better at inducing remission than placebo or mesalamine.

布地奈德缓释胶囊诱导缓解的效果明显低于传统类固醇，尤其是在病情严重的患者中。 Patients treated with budesonide extended-release capsules experienced fewer adverse effects compared with traditional steroids, and budesonide better protected adrenal function.

结论

布地奈德缓释胶囊在诱导克罗恩病缓解方面比安慰剂或美沙拉秦更有效。 Although budesonide extended-release capsules have less short-term efficacy than traditional steroids, especially in patients with severe disease or more extensive colon involvement, the likelihood of adverse events and adrenal suppression is lower.

Dosage and usage of budesonide sustained-release capsules

1. For adults with mild to moderately active Crohn's disease, take 9 mg daily for up to 8 weeks; repeat the 8-week treatment process to avoid recurrent active disease.

2. Pediatrics 8 to 17 years old with mild to moderately active Crohn's disease weighing more than 25 kg: 9 mg once daily for up to 8 weeks, then 6 mg every morning for 2 weeks.

3、维持轻度至中度克罗恩病的临床缓解：成人：每日6毫克，最长3个月;锥形完成3个月后停止。尚未证实持续治疗超过3个月可提供实质性临床益处。

The above information is integrated from the Internet and the US FDA drug instructions. It is for reference only. It is recommended to follow the doctor's advice and not to use it blindly.

Recommended hot articles:

References

Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD000296. doi: 10.1002/14651858.CD000296.pub3. Update in: Cochrane Database Syst Rev. 2015;6:CD000296. PMID: 18646064.